While a variety of PXR‐activating xenobiotics exist, they all have significant off‐target effects in vivo (e.g., drug interactions), which limits their use as clinical drugs for IBD (Cheng et al, 2012a). Here, NR1I2 is linked to inflammatory bowel disease.